Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas

While JAK 1/2 inhibitors are effective at reducing symptoms of myelofibrosis, several cases of sporadic B-cell non-Hodgkin lymphomas have been reported in treated patients.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

Long-Term Follow Up of CheckMate 205 Confirms Nivolumab Efficacy in Relapsed/Refractory Hodgkin Lymphoma

By

Similar ORR was reported for patients regardless of prior exposure to brentuximab vedotin (BV).

Long-Term Follow-Up Results of ZUMA-1 Trial

Long-Term Follow-Up Results of ZUMA-1 Trial

Frederick Locke, MD, discusses his research at the ASCO 2018 meeting.

Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma Treatment Regimens

View treatment regimens for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, including combination therapies with bortezomib and more.

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

Lenalidomide Plus Rituximab May Be As Effective As Standard of Care in Follicular Lymphoma

By

Previous studies have shown that rituximab plus lenalidomide may not only be as effective but also improve immune competence in this patient population.

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma

By

Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

By

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

Rituximab, Gemcitabine, Plus Oxaliplatin May Be an Effective First-Line Option in Elderly DLBCL

By

Rituximab, gemcitabine, plus oxaliplatin has shown high efficacy with low toxicity among elderly patients with relapsed/refractory diffuse large b-cell lymphoma in previous studies.

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

FDA Expands Tisagenlecleucel Indication To Include Relapsed/Refractory B-cell Lymphomas

By

The FDA based its approval on results of the single-arm phase 2 JULIET clinical trial.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Extranodal NK/T-cell Lymphoma

Get current treatment regimens for extranodal NK/T-cell lymphoma, which details options such as radiotherapy plus DeVic and SMILE + radiotherapy.

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia

Ixazomib, Dexamethasone, and Rituximab: Promising for Waldenstrom Macroglobulinemia

By

The median progression-free survival was not reached after a median follow-up of 22 months.

Hodgkin Lymphoma Treatment Regimens

Find comprehensive treatment regimens for Hodgkin lymphoma, including therapies such as ABVD + involved-field radiotherapy and more.

Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL

Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL

By

At time of analysis, 14 of the 22 complete responses were ongoing.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Ibrutinib and Venetoclax: A New Standard for Mantle Cell Lymphoma?

Ibrutinib and Venetoclax: A New Standard for Mantle Cell Lymphoma?

By

Preclinical models indicated that dual inhibition of BTK and BCL2 may be synergistic.

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

Brentuximab in Classical Hodgkin Lymphoma — In the Clinic

By

Brentuximab vedotin is an anti-CD30 monoclonal antibody that targets the Reed-Sternberg cells found in patients with classical HL.

Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors

Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors

By

The recommended phase 2 dose is 800 mg twice daily.

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

By

Findings from a previous study suggested that Q fever may significantly increase a person's risk of nHL.

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma

By

The FDA is reviewing a New Drug Application, which is requesting full approval for CLL/SLL and accelerated approval for follicular lymphoma.

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

By

Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Ibrutinib Plus Venetoclax Significantly Improves Complete Response Rate in Mantle Cell Lymphoma

Ibrutinib Plus Venetoclax Significantly Improves Complete Response Rate in Mantle Cell Lymphoma

By

Preclinical models predict that ibrutinib and venetoclax would have a synergistic effect in dual inhibition for mantle cell lymphoma.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs